Piper Sandler Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $3
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $7 to $3.
Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $7 to $3.
